Author
Listed:
- Fiona M. Rudkin
(Medical Research Council Centre for Medical Mycology at the University of Aberdeen)
- Ingrida Raziunaite
(Medical Research Council Centre for Medical Mycology at the University of Aberdeen
University of Edinburgh)
- Hillary Workman
(Cambridge Kendall Square)
- Sosthene Essono
(Cambridge Kendall Square
HiFiBiO)
- Rodrigo Belmonte
(Medical Research Council Centre for Medical Mycology at the University of Aberdeen
MSD Animal Health Innovation AS)
- Donna M. MacCallum
(Medical Research Council Centre for Medical Mycology at the University of Aberdeen)
- Elizabeth M. Johnson
(Science Quarter, Southmead Hospital)
- Lisete M. Silva
(Imperial College London)
- Angelina S. Palma
(NOVA University of Lisbon)
- Ten Feizi
(Imperial College London)
- Allan Jensen
(Cambridge Kendall Square
H. Lundbeck)
- Lars P. Erwig
(Medical Research Council Centre for Medical Mycology at the University of Aberdeen
Galvani Bioelectronics)
- Neil A. R. Gow
(Medical Research Council Centre for Medical Mycology at the University of Aberdeen
University of Exeter)
Abstract
The high global burden of over one million annual lethal fungal infections reflects a lack of protective vaccines, late diagnosis and inadequate chemotherapy. Here, we have generated a unique set of fully human anti-Candida monoclonal antibodies (mAbs) with diagnostic and therapeutic potential by expressing recombinant antibodies from genes cloned from the B cells of patients suffering from candidiasis. Single class switched memory B cells isolated from donors serum-positive for anti-Candida IgG were differentiated in vitro and screened against recombinant Candida albicans Hyr1 cell wall protein and whole fungal cell wall preparations. Antibody genes from Candida-reactive B cell cultures were cloned and expressed in Expi293F human embryonic kidney cells to generate a panel of human recombinant anti-Candida mAbs that demonstrate morphology-specific, high avidity binding to the cell wall. The species-specific and pan-Candida mAbs generated through this technology display favourable properties for diagnostics, strong opsono-phagocytic activity of macrophages in vitro, and protection in a murine model of disseminated candidiasis.
Suggested Citation
Fiona M. Rudkin & Ingrida Raziunaite & Hillary Workman & Sosthene Essono & Rodrigo Belmonte & Donna M. MacCallum & Elizabeth M. Johnson & Lisete M. Silva & Angelina S. Palma & Ten Feizi & Allan Jensen, 2018.
"Single human B cell-derived monoclonal anti-Candida antibodies enhance phagocytosis and protect against disseminated candidiasis,"
Nature Communications, Nature, vol. 9(1), pages 1-16, December.
Handle:
RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-07738-1
DOI: 10.1038/s41467-018-07738-1
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-07738-1. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.